Disclosures: David Twitchell: Nothing to Disclose, Dakota Bigham: Nothing to Disclose, Rodolfo Singleterry: Nothing to Disclose, Owais Syed: Nothing to Disclose, Eugenia Tsai: Nothing to Disclose, Fabian Rodas: Nothing to Disclose, Carmen Landaverde: Nothing to Disclose, Jan Petrasek: Nothing to Disclose, Eric Lawitz: Nothing to Disclose, Andres Gomez-Aldana: Nothing to Disclose, Emma Pham: Nothing to Disclose, Amanda Matthews: Nothing to Disclose, Jamiel Ramos: Nothing to Disclose, Kelly Velasquez: Nothing to Disclose, ELIZABETH CALDERA: Nothing to Disclose, Jonathan Inskeep: Nothing to Disclose, Clarissa Vaughn: Nothing to Disclose, Lisa Pedicone: Nothing to Disclose, Fred Poordad: Nothing to Disclose 497 AVOIDING PHLEBOTOMY ENTIRELY: VALIDATION OF A POINT-OF-CARE MEASURE OF APRI & FIB4 FROM FINGER-PRICK BLOOD David Smookler 1 Sarah Tran 2 Bethany Barber 2 Ahreni Saunthar 2 Magdalena Kuczynski 2 Andrew Mendlowitz 2 Aaron Vanderhoff 2 Mia Biondi 2 Camelia Capraru 2 Jordan Feld 3 , 1 Toronto Centre for Liver Disease, 2 VIRCAN/Toronto Centre for Liver Disease, 3 Toronto General Hospital Background: Achieving the World Health Organizations viral hepatitis elimination goals requires decentralized treatment
How Peptides Enhance Results From BHRT, Weight Loss, and Surgery Peptide therapy is designed to work with your other wellness or aesthetic treatments, not separately
How to pack your injections in your carry-on
Which types of antipsychotics (first or second generation) are more likely to cause an increase in lipid levels
Transgenic Res 20(3):665673
